DK1684770T3 - Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft - Google Patents

Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft

Info

Publication number
DK1684770T3
DK1684770T3 DK04791108T DK04791108T DK1684770T3 DK 1684770 T3 DK1684770 T3 DK 1684770T3 DK 04791108 T DK04791108 T DK 04791108T DK 04791108 T DK04791108 T DK 04791108T DK 1684770 T3 DK1684770 T3 DK 1684770T3
Authority
DK
Denmark
Prior art keywords
glucan
beta
cancer
oligo
monoclonal antibodies
Prior art date
Application number
DK04791108T
Other languages
English (en)
Inventor
Jean-Claude Yvin
Edouard Panak
Vaclav Vetvicka
Original Assignee
Goemar Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goemar Lab Sa filed Critical Goemar Lab Sa
Application granted granted Critical
Publication of DK1684770T3 publication Critical patent/DK1684770T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK04791108T 2003-10-30 2004-10-29 Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft DK1684770T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/698,034 US7070778B2 (en) 2003-10-30 2003-10-30 Therapeutical combination against cancer
PCT/EP2004/013119 WO2005049044A1 (en) 2003-10-30 2004-10-29 Oligo-beta-(1, 3) -glucan and monoclonal antibodies against cancer

Publications (1)

Publication Number Publication Date
DK1684770T3 true DK1684770T3 (da) 2009-11-09

Family

ID=34550517

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04791108T DK1684770T3 (da) 2003-10-30 2004-10-29 Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft

Country Status (11)

Country Link
US (1) US7070778B2 (da)
EP (1) EP1684770B1 (da)
AT (1) ATE435020T1 (da)
CY (1) CY1109817T1 (da)
DE (1) DE602004021842D1 (da)
DK (1) DK1684770T3 (da)
ES (1) ES2328822T3 (da)
PL (1) PL1684770T3 (da)
PT (1) PT1684770E (da)
SI (1) SI1684770T1 (da)
WO (1) WO2005049044A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US20090047288A1 (en) * 2006-06-15 2009-02-19 Jun Yan Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity
CN100457766C (zh) * 2006-09-26 2009-02-04 重庆邮电大学 非天然活性葡聚四糖烷基苷类化合物及其制备方法和应用
FR2910322B1 (fr) * 2006-12-22 2009-10-30 Mer Soc Par Actions Simplifiee Utilisation d'oligo-b-(1,3)-glucanes modifies pour le traite traitement de maladies du systeme immunitaire, oligo-b-(1,3) glucane-(1,3)-mannose, oligo-b-(1,3)-glucane-(1,3)-mannitol et leurs derives, ...
WO2009035617A1 (en) * 2007-09-10 2009-03-19 Barofold, Inc. High-pressure refolding of monoclonal antibody aggregates
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
CN102308800A (zh) * 2010-06-30 2012-01-11 中国科学院大连化学物理研究所 一种可德兰寡糖的应用
CN102405906B (zh) * 2011-10-28 2013-10-23 海南正业中农高科股份有限公司 一种用于抗胡椒病毒病的壳寡糖组合物及其用途和方法
CN102415384B (zh) * 2011-10-28 2013-12-25 海南正业中农高科股份有限公司 壳寡糖用于调节作物生长的用途
WO2014147199A1 (en) 2013-03-20 2014-09-25 Bioatlantis Ltd A non-nematicidal composition and use thereof
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
EP3551685A1 (en) * 2016-12-07 2019-10-16 Innate Biotherapeutics, LLC ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES
EP3582810A4 (en) 2016-12-07 2020-08-19 Innate Biotherapeutics, LLC Ss-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45706A (en) * 1865-01-03 Improvement in apparatus for aerating dough
CA2283452A1 (en) 1997-03-04 1998-09-11 Yveta Germano Composition and method for treating cancer and immunological disorders resulting in chronic conditions
FR2777281B1 (fr) 1998-04-14 2000-06-30 Goemar Lab Sa Procede de synthese du d-laminaribiose
FR2804684B1 (fr) 2000-02-04 2002-06-28 Goemar Lab Sa Procede pour la preparation de derives fonctionnalises de beta-(1,3)-glucanes
US6454697B1 (en) * 2000-07-18 2002-09-24 Dai-Yuan Wang Cardiac support device and method
US6660722B2 (en) 2001-11-30 2003-12-09 Laboratoires Goemar S.A. Therapeutical treatments

Also Published As

Publication number Publication date
US7070778B2 (en) 2006-07-04
EP1684770B1 (en) 2009-07-01
SI1684770T1 (sl) 2009-12-31
DE602004021842D1 (de) 2009-08-13
PL1684770T3 (pl) 2009-12-31
WO2005049044A1 (en) 2005-06-02
PT1684770E (pt) 2009-09-29
ES2328822T3 (es) 2009-11-18
EP1684770A1 (en) 2006-08-02
US20050095250A1 (en) 2005-05-05
ATE435020T1 (de) 2009-07-15
CY1109817T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
PL374865A1 (en) Treatment of tnf alpha related disorders
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DK1734995T3 (da) Monoklonale antistoffer og hepatocyytvækstfaktor
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
MY154009A (en) Anti-alpha v beta 6 antibodies
BR0011838A (pt) Elementos misturadores estáticos empilhados
ATE470676T1 (de) Anti-vegf-2 antikörper
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
EA200601386A1 (ru) ИММУНОГЛОБУЛИНЫ ПРОТИВ АНТИГЕНА EpCAM
ATE392219T1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
DK1545609T3 (da) Antistoffer rettet mod oxideret apolipoprotein B
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
AU2013204147B2 (en) Treatment of TNFalpha related disorders
ATE490981T1 (de) Criptospezifische antikörper